Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.80 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.80 |
| ▸ | CTSD | P07339 | 8/20 | 0.77 |
| ▸ | REN | P00797 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240351 | 0.91 | BACE1 (0.81) | BACE1BACE2CTSD | |
| SCHEMBL23190513 | 0.90 | BACE1 (0.83) | BACE1BACE2CTSDREN | |
| SCHEMBL4318188 | 0.89 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL20625457 | 0.89 | BACE1 (0.83) | BACE1BACE2CTSD | |
| SCHEMBL4522306 | 0.88 | BACE1 (0.75) | BACE1BACE2CTSDREN | |
| SCHEMBL4307456 | 0.87 | BACE1 (1.00) | BACE1BACE2CTSDREN | |
| SCHEMBL4782211 | 0.87 | BACE1 (0.74) | BACE1BACE2CTSDREN | |
| SCHEMBL3537470 | 0.86 | BACE1 (0.75) | BACE1BACE2CTSDREN | |
| SCHEMBL8238880 | 0.86 | BACE1 (0.85) | BACE1BACE2CTSDREN | |
| SCHEMBL3583089 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142505-B2 | Compositions for APP-selective BACE inhibition and uses therefor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| US-20190077766-A1 | Compositions For APP-Selective BACE Inhibition And Uses Therefor | NANTNEURO, LLC | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077766-A1 | Compositions For APP-Selective BACE Inhibition And Uses Therefor | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 88/4885 |
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | APP, BACE1, BACE2 | BACE1 2/4885BACE2 3/4885CTSD 717/4885 |
| US-11142505-B2 | Compositions for APP-selective BACE inhibition and uses therefor | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.